Print Page   |   Contact Us   |   Report Abuse   |   Sign In   |   Register
ASAP Blog
Blog Home All Blogs
Search all posts for:   

 

View all (249) posts »
 

Chiasma Taps Roche for Phase III Neuroendocrine Tumor Drug

Posted By Administration, Friday, June 20, 2014
Originally posted on 2/18/2013

Chiasma has turned to ASAP Corporate Member Roche to commercialize its acromegaly and neuroendocrine tumor drug Octreolin. In exchange for a worldwide exclusive license to Octreolin, Roche will initially pay Chiasma $65 million and possibly up to an additional $530 million with the accomplishment of certain development and commercial milestones. In addition, Chiasma will also get tiered, double-digit royalties if/when Octreolin gets to market.

This post has not been tagged.

Share |
Permalink | Comments (0)
 
For more information email us at info@strategic-alliances.org or call +1-781-562-1630